Aprea Therapeutics (APRE) AI Stock Analysis

• Market Cap: $6.29M
• Dividend Yield: N/A
• Average Volume (3M): 55.77K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.93
• Revenue Growth: -62.75%
• EPS Growth: 23.87%
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.47
• Shares Outstanding: 6,993,838
• 10 Day Avg. Volume: 84,633
• 30 Day Avg. Volume: 55,770
• PEG Ratio: 0.03
• Price to Book (P/B): 0.94
• Price to Sales (P/S): 12.06
• P/FCF Ratio: -1.34
• Enterprise Value/Market Cap: -0.88
• Enterprise Value/Revenue: -11.31
• Enterprise Value/Gross Profit: 0.88
• Enterprise Value/Ebitda: 0.40
• 1Y Price Target: $5.00
• Price Target Upside: 455.56% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: $0.91 ▲(0.78% Upside)

APRE scores low primarily due to weak financial performance (ongoing losses and cash burn despite being debt-free) and a bearish technical setup (price below key moving averages with negative MACD). Valuation is constrained by negative earnings and no dividend, partially offset by moderately positive corporate updates and financing extending cash runway.

Positive Factors

Debt-free balance sheet

Aprea's lack of debt materially reduces refinancing and solvency risk, giving management flexibility to prioritize R&D or pursue partnerships without mandatory interest payments. Over 2–6 months this structural strength lowers bankruptcy risk and supports strategic options for financing or collaborations.

Promising APR-1051 clinical activity

Early signs of disease stabilization in heavily pretreated patients support APR-1051's biological rationale and provide de-risking toward proof-of-concept. Durable clinical activity can unlock partnerships, non-dilutive funding, or accelerated development pathways, materially improving long-term program prospects.

Clear development roadmap and experienced team

A defined 2026 roadmap and a management team with deep oncology experience increase the likelihood of disciplined execution, efficient trial design, and informed go/no-go decisions. This structural competency supports credible milestone delivery and enhances chances of partnerships or asset value realization.

Negative Factors

Sustained negative cash flow

Persistent negative operating and free cash flow means the company must secure external funding to sustain operations. Over the next several quarters this structural cash burn constrains strategic flexibility, increases execution risk for trials, and elevates the probability of dilutive financings.

Very small and declining revenue base

As a pre-commercial biotech with declining revenue, Aprea lacks meaningful internal cash generation to fund development. This structural revenue weakness forces reliance on external capital or partnerships, limiting the company's ability to scale programs or invest concurrently across its pipeline.

Material equity erosion

Significant erosion of the capital base signals prior heavy losses and raises the likelihood of further dilutive financings to fund trials. Structurally, diminished equity reduces buffer against shocks, weakens bargaining power with partners, and increases governance and financing risks over the coming 2–6 months.

Aprea Therapeutics Business Overview & Revenue Model

Company Description

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

How the Company Makes Money

Aprea Therapeutics makes money through the development and commercialization of its proprietary cancer therapeutics. The company generates revenue mainly from partnerships and collaborations with larger pharmaceutical companies, which may include license agreements, milestone payments, and royalties from the commercialization of its drug candidates. Aprea also seeks funding through grants and research collaborations to support its ongoing research and development efforts. Furthermore, successful clinical trials leading to market approval of its products can significantly increase its revenue through direct sales and licensing deals.

Aprea Therapeutics Financial Statement Overview

Summary

Aprea Therapeutics faces significant financial challenges with no meaningful revenue generation and consistent losses. The strong balance sheet with no debt provides some stability, but negative cash flows and lack of profitability present ongoing risks. The company is heavily reliant on external financing to support operations.

Income Statement

Aprea Therapeutics has faced significant challenges in generating revenue, with no revenue reported in recent years except for a minimal amount in 2023. The company has consistently reported negative net income, indicating ongoing losses. Margins such as gross profit, EBIT, and EBITDA are not meaningful due to negligible or zero revenue, highlighting the company's struggle to achieve profitability.

Balance Sheet

The company maintains a strong equity position with no debt, resulting in a debt-to-equity ratio of zero. However, the return on equity (ROE) is negative due to consistent losses. The equity ratio is favorable, indicating a healthy balance between equity and total assets. Despite these strengths, the lack of revenue and profitability remains a concern.

Cash Flow

Aprea Therapeutics has negative operating and free cash flows, reflecting cash burn typical of biotech firms in development phases. The operating cash flow to net income ratio is negative due to losses, and free cash flow growth is also negative. While financing activities have provided cash inflows, the company’s cash flow position remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	488.24K	1.50M	583.23K	0.00	0.00	0.00
Gross Profit	-6.27M	-7.86M	576.18K	-16.40M	-271.68K	-229.61K
EBITDA	-13.65M	-14.30M	-14.28M	-37.37M	-36.86M	-53.25M
Net Income	-13.04M	-12.96M	-14.29M	-112.66M	-36.54M	-53.92M
Balance Sheet
Total Assets	14.32M	23.98M	22.65M	30.16M	56.82M	92.81M
Cash, Cash Equivalents and Short-Term Investments	13.72M	22.85M	21.61M	28.79M	53.08M	89.02M
Total Debt	0.00	0.00	0.00	0.00	190.47K	335.16K
Total Liabilities	2.68M	4.67M	4.39M	4.51M	7.32M	15.41M
Stockholders Equity	11.64M	19.31M	18.26M	25.64M	49.51M	77.40M
Cash Flow
Free Cash Flow	-13.54M	-13.57M	-12.27M	-25.01M	-37.69M	-41.83M
Operating Cash Flow	-13.54M	-13.56M	-12.18M	-25.01M	-37.69M	-41.80M
Investing Cash Flow	0.00	-15.48K	-93.09K	0.00	0.00	-25.71K
Financing Cash Flow	945.82K	14.82M	5.14M	682.97K	1.75M	150.95K

Aprea Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APRE, the sentiment is Negative. The current price of 0.9 is below the 20-day moving average (MA) of 0.91, below the 50-day MA of 1.05, and below the 200-day MA of 1.50, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 40.31 is Neutral, neither overbought nor oversold. The STOCH value of 41.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for APRE.

Aprea Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
QNRX	52 Neutral	$6.63M	-0.02	-655.85%	―	―	-228.89%
INAB	52 Neutral	$10.24M	-0.33	-189.72%	―	―	70.57%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VYNE	49 Neutral	$18.86M	-0.72	-70.67%	―	6.29%	7.42%
NCNA	46 Neutral	$13.86M	-0.02	-179.40%	―	―	94.52%
APRE	43 Neutral	$6.29M	-0.42	-74.72%	―	-62.75%	23.87%

Aprea Therapeutics Corporate Events

Aprea Therapeutics Updates Oncology Pipeline and Strategy Outlook

On January 9, 2026, Aprea Therapeutics updated its corporate presentation, outlining a development roadmap through 2026 that highlights multiple DDR-focused drug candidates and clinical milestones in early-stage oncology trials. The company detailed progress on its ATR inhibitor ATRN-119, for which further monotherapy enrollment has been paused in favor of exploring combination strategies, and on its WEE1 inhibitor APR-1051, which is being advanced toward clinical proof-of-concept as a potentially safer alternative in a target class historically limited by toxicity. The refreshed deck emphasizes Aprea’s strategy to capitalize on synthetic lethality as a validated cancer-killing approach, positioning the firm to benefit from rising global cancer incidence and sustained demand for targeted therapies, while showcasing an experienced management team and board with deep expertise in oncology drug development and commercialization.

The most recent analyst rating on (APRE) stock is a Hold with a $0.89 price target. To see the full list of analyst forecasts on Aprea Therapeutics stock, see the APRE Stock Forecast page.

Aprea Therapeutics Secures $3.1M in Private Placement

On December 8, 2025, Aprea Therapeutics entered into a securities purchase agreement with accredited investors and company insiders to issue and sell 2,623,023 shares of common stock and warrants in a private placement, expected to close on December 10, 2025, for approximately $3.1 million. This financing is anticipated to extend Aprea’s cash runway into Q1 2027, supporting its clinical programs and general corporate purposes, with Maxim Group LLC acting as the sole placement agent.

The most recent analyst rating on (APRE) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Aprea Therapeutics stock, see the APRE Stock Forecast page.

Aprea Therapeutics Reports Q3 Results and Clinical Updates

On November 12, 2025, Aprea Therapeutics reported its third-quarter financial results and provided updates on its clinical programs. The company highlighted progress in its WEE1 and ATR inhibitor programs, with APR-1051 showing promising results in a Phase 1 trial and ATRN-119 reaching a recommended Phase 2 dose. Aprea’s financials showed a reduction in operating loss and R&D expenses compared to the previous year, with cash reserves expected to support operations into late 2026.

The most recent analyst rating on (APRE) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Aprea Therapeutics stock, see the APRE Stock Forecast page.

Aprea Therapeutics Reports Promising Trial Results for APR-1051

On October 24, 2025, Aprea Therapeutics announced promising early results from their ACESOT-1051 trial for the WEE1 Kinase Inhibitor APR-1051, showing that 3 out of 4 patients achieved stable disease at a 100 mg dose level. The trial, which focuses on heavily pretreated patients with gastrointestinal and gynecologic malignancies, observed disease stabilization in tumors with specific mutations, supporting the mechanistic rationale for APR-1051’s development. The company is encouraged by these findings and is progressing to a higher dose level in the ongoing study.

The most recent analyst rating on (APRE) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Aprea Therapeutics stock, see the APRE Stock Forecast page.

Aprea Therapeutics Shifts Focus to Combination Therapies

On October 15, 2025, Aprea Therapeutics announced the recommended Phase 2 dose of 1,100 mg once daily for ATRN-119 in its ongoing ABOYA-119 study for advanced solid tumors. The company is pausing further monotherapy enrollment to focus on combination therapies, leveraging ATRN-119’s potential synergistic effects with DNA-damaging agents. This strategic shift aims to enhance the therapeutic potential of ATRN-119, with ongoing discussions for combination studies in HPV+ head and neck cancer and other indications.

The most recent analyst rating on (APRE) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Aprea Therapeutics stock, see the APRE Stock Forecast page.